» Articles » PMID: 18647181

Intra-arterial Milrinone for Reversible Cerebral Vasoconstriction Syndrome

Overview
Journal Headache
Publisher Wiley
Specialties Neurology
Psychiatry
Date 2008 Jul 24
PMID 18647181
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Reversible cerebral vasoconstriction syndrome (RCVS) usually presents with recurrent thunderclap headaches and is characterized by multifocal and reversible vasoconstriction of cerebral arteries that can sometimes evolve to severe cerebral ischemia and stroke. We describe the case of a patient who presented with a clinically typical RCVS and developed focal neurological symptoms and signs despite oral treatment with calcium channel blockers. Within hours of neurological deterioration, she was treated with intra-arterial milrinone, a phosphodiesterase inhibitor, which resulted in a rapid and sustained neurological improvement.

Citing Articles

Treatment-Related Reversible Cerebral Vasoconstriction Syndrome.

Avola G, Pezzini A J Clin Med. 2024; 13(19).

PMID: 39407990 PMC: 11478140. DOI: 10.3390/jcm13195930.


Reversible cerebral vasoconstriction syndrome post-cardiac transplantation: a therapeutic dilemma: case report.

Montarello N, Irvine I, Warner V, Hare J, Kaye D, Cloud G BMC Neurol. 2024; 24(1):277.

PMID: 39123195 PMC: 11312223. DOI: 10.1186/s12883-024-03780-3.


Reversible Cerebral Vasoconstriction Syndrome in Early Pregnancy Treated with Endovascular Therapy.

Fujiwara S, Ohara N, Kono T, Inui R, Imamura H, Kawamoto M J Neuroendovasc Ther. 2023; 14(5):177-182.

PMID: 37502693 PMC: 10370675. DOI: 10.5797/jnet.cr.2019-0108.


Intra-arterial vasodilators infusion for management of reversible cerebral vasoconstriction syndrome in a 12-year-old girl: A case report.

Rizzati F, Marie G, Chanez V, Ferry T, Natterer J, Longchamp D Front Pediatr. 2023; 11:1042509.

PMID: 36937972 PMC: 10020348. DOI: 10.3389/fped.2023.1042509.


Reversible cerebral vasoconstriction syndrome associated with tetrodotoxin poisoning: A case report.

Kakehi E, Matsumoto M, Taniguchi S, Akamatsu Y, Sakurai S, Hirotani A J Am Coll Emerg Physicians Open. 2022; 2(6):e12627.

PMID: 34988549 PMC: 8702407. DOI: 10.1002/emp2.12627.